T.R.8.C.E.
The Vibe
The Field Guide

Ozempic, Mounjaro, and the one everyone is waiting for.

Three drugs. Three generations. One switch at a time, so it finally makes sense. This is the whole GLP family in plain English.

The Field Guide . July 13, 2026 . 4 min read
You have heard of three.
GLP-1 Semaglutide GLP-2 Tirzepatide GLP-3 Retatrutide
One idea, built three times. Here is each one, one switch at a time.

You have seen the names a hundred times. Ozempic. Mounjaro. And a third one people keep whispering about. They sound like a wall of chemistry. They are actually the same idea, built three times, each one adding a single new trick.

Your body has a handful of switches that control hunger, blood sugar, and how fast you burn energy. Each generation of these drugs flips one more of them, so the market just numbers the generations: GLP-1, GLP-2, GLP-3. That is all those labels mean, generation one, two, and three. Here is each one.

The three generations, one switch at a time

1
Generation 1 · 2017 · Single
GLP-1
Semaglutide
OzempicWegovy
Appetite
OFF
Shuts your appetite off. That's it. One job.

Semaglutide started the whole wave. Its one switch quiets hunger, so you feel full sooner and eat less without fighting yourself. In the trials that got it approved, people lost around 15 percent of their body weight. One switch, one clean job, and it changed the world.

2
Generation 2 · 2022 · Dual
GLP-2
Tirzepatide
MounjaroZepbound
Appetite
OFF
Blood sugar
STEADY
Appetite off, plus it steadies your blood sugar.

Tirzepatide keeps the appetite switch and adds a second that helps the body handle blood sugar and insulin. Stacked together, trial weight loss climbed to about 22.5 percent, meaningfully more than the generation before it. Two switches, working together.

3
Generation 3 · Newest · Triple
GLP-3
Retatrutide
No brand name yet
Appetite
OFF
Blood sugar
STEADY
Burn rate
UP
All that, plus it turns your body into a furnace.

Retatrutide keeps both earlier switches and adds a third that raises how much fuel you burn even at rest. In trials that pushed mean weight loss to roughly 28 percent, the highest of the three. It has no brand name yet because it is still finishing its final round of testing and is not approved. That is the one everyone is waiting for.

The wrap-up
The whole family, at a glance
Nobody has to memorize a receptor. You just count the switches: one, two, three.
Side by side
 
SemaglutideGLP-1
TirzepatideGLP-2
RetatrutideGLP-3
Switches
1
2
3
Weight loss
~15%
~22.5%
~28%
Half-life
7 days
5 days
6 days
Status
Approved
Approved
In trials
Read the shelf
"GLP-1"meansSemaglutide
The single. Sold as Ozempic and Wegovy. Also listed as Sema or NN9535.
"GLP-2"meansTirzepatide
The dual. Sold as Mounjaro and Zepbound. Also listed as Tirz, TZP, or LY3298176.
"GLP-3"meansRetatrutide
The triple. No brand name yet. Also listed as Reta or LY3437943.
More switches has meant more weight lost in the trials so far. It also means a newer, less-traveled safety record, and the whole class shares the same common effects, mostly nausea that eases as the body adjusts. Newer is not automatically better for any one person. It is just further along the same line.
Now put it to work.
You know all three. Whichever one you are researching, the moment powder meets water the math is identical, and getting it exactly right is the whole game.
SemaglutideGLP-1 · reconstitute it right, in one drag › TirzepatideGLP-2 · reconstitute it right, in one drag › RetatrutideGLP-3 · reconstitute it right, in one drag ›

Know exactly what you are drawing

Pick your compound. Pour the water. TR8CE does the math and draws the exact dose on the right syringe. On your phone, nothing saved.

Open the calculator
Nothing to sign up for. Only you hold the key.

What this does not support

  • This is a plain-language explainer of how these compounds are categorized, not medical or dosing advice.
  • Trial weight-loss figures are reported as published results under clinical monitoring, not an outcome anyone should expect or a reason to choose one compound.
  • Retatrutide is investigational and not an approved medicine. Semaglutide and tirzepatide are prescription drugs. TR8CE has no affiliation with any manufacturer.
  • Research compounds are not for human consumption. Consult a qualified professional.